Compare National Beverage Corp. (FIZZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Pfizer Inc — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.91B), while Pfizer Inc trades at $26.59 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 53× National Beverage Corp.'s market cap, and Pfizer Inc pays a 6.36% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | PFE | |
|---|---|---|
Market Cap | $2.91B | $154.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $28.56 |
52-Week Low | $30.53 | $23.60 |
Enterprise Value | $2.62B | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.13, up 0.53% today, with neutral technical signals and mixed earnings performance. The company reported $1.20B revenue and $186.82M net income for 2025, maintaining strong profitability margins. Recent news highlights a special $3.25 dividend announcement amid concerns about LaCroix brand stagnation and competitive pressures.
The stock faces headwinds from declining volumes and muted growth prospects, offset by shareholder returns via dividends. Analyst sentiment is cautious with 50% sell ratings. Key risks include consumer weakness and tariff impacts, while valuation at 15.84x P/E appears reasonable given current fundamentals.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
